Taxotere (docataxel), a chemotherapy treatment widely prescribed to breast cancer patients in the United States, is now known to cause permanent hair loss as a common side effect. Taxotere has been found to be more toxic, more prone to cellular drug resistance, and less effective than similar drugs. Never warned of the risk of permanent hair loss from Taxotere, American patients are now seeking justice through filing Taxotere hair lawsuits against Sanofi.
First approved by the FDA in 1996, Taxotere was promoted as a superior alternative to Taxol (paclitaxel), another chemotherapy treatment used to combat breast cancer. Now experts say Taxotere is MORE DANGEROUS and NO MORE EFFECTIVE than alternative treatments. A study published in the New England Journal of Medicine in 2008 ("Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer") even showed Taxotere is less effective than its safer alternative, paclitaxel. Combined with the risk of permanent hair loss, researchers now believe Taxotere offers no advantages over other breast cancer treatments.
The drug's maker, Sanofi, first learned of the risk of permanent Taxotere hair loss or alopecia in 2005, yet never warned American consumers. (In comparison, consumers in Canada and Europe were warned of the risk for permanent hair loss for Taxotere.) Temporary hair loss is counted among the most distressing side effects of chemotherapy; Taxotere permanent hair loss extends this suffering indefinitely, resulting in lifelong depression and negative body image.
Patients undergoing Taxotere treatment had a right to know they were being exposed to a risk for permanent hair loss. Had they been informed, patients undergoing Taxotere chemotherapy could have made an informed decision about whether to accept the permanent hair loss risk from Taxotere or choose an alternate therapy. Instead, thousands of patients were exposed to this significant and distressing signification with no knowledge whatsoever.
The makers of Taxotere have a long history of implementing illegal and unethical business practices. Experts say Taxotere was flawed from the start, due to a lack of adequate testing to determine the drug's safety. Sanofi sold Taxotere without disclosing known risks, failing to warn providers and patients of the danger of permanent Taxotere hair loss. Evidence presented in Taxotere lawsuits indicates the drug was promoted illegally beginning in 1996, when physicians were allegedly rewarded with grants, speaker fees, sports tickets and other kickbacks for promoting the drug for off-label uses.
American patients were led to believe Taxotere was superior to other treatment options and that Taxotere hair loss would be temporary. Fully aware of the risk of permanent Taxotere hair loss, Sanofi directly caused thousands of patients to be exposed to this toxic drug. The company reaped the benefits of its deception, earning a peak of $1.4 billion in annual Taxotere sales by 2004.
Today, consumers are filing Taxotere lawsuits against Sanofi to recover meaningful compensation for the harm suffered as a result of permanent Taxotere hair loss. When a corporation benefits at the expense of American consumers, our Taxotere attorneys make it their mission to hold the corporation accountable. If you or a loved one suffers from permanent Taxotere hair loss, contact our firm today to learn about your legal options. Read more about who qualifies to file Taxotere Hair Lawsuits against Sanofi.
Choosing an attorney to represent your family in a Taxotere hair loss claim is a major decision and we advise taking your time to find the right fit. Choosing a firm that has a significant track record of success in past pharmaceutical and products liability cases will ensure you are in good hands. Read more about how to choose a Taxotere lawyer.
A leader in cancer research at Harvard University asserts that perhaps 10,000 cases of ovarian cancer can be blamed each year on perineal talc use in the US. Despite the existence of evidence that talc-based products are dangerous and can cause cancer, talc is not regulated in the US. The American Cancer Society estimates that in 2013, about 22,240 new cases of ovarian cancer will be diagnosed, while 14,030 women will die as a result of ovarian cancer in the US.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Physiomesh is a form of surgical mesh that has been used in hernia repair surgeries. Ethicon Physiomesh was used in ventral hernia repair and has been pulled from the market due to a high failure rate. Persons with Ethicon Physiomesh have experienced an array of complications that include pain, infection, hernia recurrence, adhesion or scar-tissue buildup, intestinal blockage, bleeding, perforation, organ damage, and the need for revision surgery.